Product Information
DROXIDOPA 300 MG CAPSULE is a generic product labeled by Sun Pharmaceutical Industries Inc., priced at $2.6037 per EA under NDC 63304011290. Its NADAC has been published 140 times since Jun 21, 2023.
FDA first approved this application on Feb 18, 2021. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
300 ug/1
Manufacturer
Sun Pharmaceutical Industries Inc.NDC
63304011290
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
2/18/2026
Active Ingredients
DROXIDOPAApproval Type
Generic (ANDA)
FDA Application
ANDA214384FDA Approved
2/18/2021
TE Code
AB
On Market Since
2/18/2021
Pharmacological Classes
Price Statistics
The NADAC for DROXIDOPA 300 MG CAPSULE has been published 140 times since Jun 21, 2023, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $2.6037 per EA |
|---|---|
| All-time high | $3.0478 (Nov 13, 2024) |
| All-time low | $2.1966 (Sep 17, 2025) |
| 52-week high | $2.6037 |
| 52-week low | $2.1966 |
| Median price | $2.5551 |
| Average price | $2.5628 |
| Largest weekly change | +12.0% (Aug 21, 2024) |
| Weeks tracked | 140 |
| Tracking since | Jun 21, 2023 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
+15.9%
3Y
+1.9%
5Y
N/A
All
+1.9%
Last surveyed Feb 18, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 18% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of DROXIDOPA 300 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for DROXIDOPA 300 MG CAPSULE, manufactured by Sun Pharmaceutical Industries Inc., is $2.6037 per EA (NDC 63304011290), effective Feb 18, 2026.
How has the price of DROXIDOPA 300 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for DROXIDOPA 300 MG CAPSULE has held within roughly two percent of its current level. It has been tracked across 140 weekly CMS publications since Jun 21, 2023.
What are the highest and lowest recorded NADAC prices for DROXIDOPA 300 MG CAPSULE?
Since Jun 21, 2023, the NADAC for DROXIDOPA 300 MG CAPSULE has ranged from a low of $2.1966 (Sep 17, 2025) to a high of $3.0478 (Nov 13, 2024), with a median of $2.5551 per EA.
Are there cheaper alternatives to DROXIDOPA 300 MG CAPSULE?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, DROXIDOPA 300 MG CAPSULE, is $2.1456 per EA — about 18% below DROXIDOPA 300 MG CAPSULE.
Who manufactures DROXIDOPA 300 MG CAPSULE?
DROXIDOPA 300 MG CAPSULE (NDC 63304011290) is labeled by Sun Pharmaceutical Industries Inc., and CMS classifies it as a generic product.